



KarXT for Schizophrenia

Stakeholder List

ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.

The following is a list of organizations from which ICER has requested input as well as those that have provided public comments during the review. All of the organizations and individuals below have been invited to provide input, however, it should not be assumed that they have responded to ICER's outreach or agreed to participate in this review.

- Cerevel Therapeutics
- Fabre-kramer Pharmaceuticals
- Hearing Voices Network USA
- Karuna Pharmaceuticals
- MassHealth
- Merck & Co.
- National Alliance on Mental Illness (NAMI)
- Otsuka Pharmaceuticals
- Schizophrenia & Psychosis Action Alliance (S&PAA)
- The STARR Coalition
- Veterans Affairs

We spoke with several additional experts in the preparation of this report. Of them, the following individuals have agreed to be identified as having spoken with ICER:

- Christoph Correll, MD, Professor, Institute of Behavioral Science, Feinstein Institutes for Medical Research; Medical Director, Recognition and Prevention (RAP) Program, Zucker Hillside Hospital; Professor of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
- Andrew Davies, MSc, Senior Health Economist, HEHTA, University of Glasgow
- Abigail Donovan, MD, Director of Child Psychiatry Emergency Services; Director of Clinical Services, Psychosis Clinical and Research Program; Associate Director, Acute Phsychiatry Service





- Oliver Freudenreich, MD, Co-Director, MGH Psychosis Clinical and Research Program;
 Director, MGH Fellowship in Public and Community Psychiatry; Associate Professor of Psychiatry, Harvard Medical School
- **John Kane, MD**, Co-Director and Professor, Institute of Behavioral Science, Feinstein Institutes for Medical Research; Professor, Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; Professor, Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
- Katherine Koh, MD, MSC, Psychiatrist, Boston Health Care for the Homeless Program;
 Massachusetts General Hospital
- **Kim Mueser, PhD**, Clinical Psychologist; Professor at the Center for Psychiatric Rehabilitation, Boston University

To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.

None of these individuals or organizations is responsible for the final content of ICER's report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit ICER's website.